Should CGRP mAbs be first-line preventive treatment for migraine?DELIVER results confirm eptinezumab efficacy across sub-groups Sustained benefits of erenumab vs oral preventives Daily headache does not impede response to galcanezumab Interim PEARL analysis supports real world efficacy of fremanezumab Further evidence of CGRP rise after mAb treatment Trigeminal symptoms may predict anti-CGRP mAb response Eligible patients with migraine still miss out on preventive therapies

CGRP in cluster headache

22 January 2020 | Videos

In the third in his series of videos about the future of CGRP therapies, Peter Goadsby describes the research that led to the approval of galcanezumab for the treatment of episodic cluster headache and looks forward to better understanding of how treatment can be optimised for patients most likely to benefit.

Educational Partners and Supporters (others pending) Amgen

Amgen

Editorial PolicyCGRP Forum is an expert resource for clinicians and healthcare professionals working with migraine patients. All patients should discuss their medication with their healthcare professional. Unless otherwise indicated, opinions expressed in the CGRP Education and Research Forum are those of the contributors. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the CGRP Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

© 2022 | Privacy Policy | Editorial Policy | Governance | Disclaimer Statement | Partnership & Outreach |